Second SISAQOL-IMI Consensus Meeting
On 16 and 17 March, the SISAQOL-IMI consortium will convene virtually for a second consensus meeting involving all 41 members.
Standardizing the design, analysis, and interpretation of patient-reported outcomes in cancer clinical trials
Patient-reported outcomes, or PROs, are important considerations when new cancer therapies are being investigated, including in benefit and risk assessments. PROs include how patients themselves experience and report their symptoms, as well as other health-related quality of life (HRQOL) issues